- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Oxonica Awarded ISO9001 Certification
Oxford, UK | Posted on March 14, 2006
Oxonica plc, a leading International nanomaterials group, is delighted to announce that it has been awarded ISO9001 certification for its UK based activities in the research and development, manufacture and supply of innovative commercial solutions in nanomaterials and associated consultative services. Oxonica were accredited by Moody International.
“Nanotechnology is a fast growing, fledgling industry,” said Dr Kevin Matthews, Oxonica’s CEO. “It is therefore very reassuring for our customers and investors to know that Oxonica has rigorous quality control procedures in place meeting the globally recognized and respected ISO9001 standards at all stages from consultation through research and development to final products.”
Thanks to its origins as a spin-out from Oxford University, England in 1999, Oxonica has been built on a foundation of solid scientific procedures and protocols which is why it was able to achieve ISO 9001 in only six months.
Oxonica (AIM: OXN.L) is one of the leading European nanomaterials groups with products already launched into international markets. It was spun-out from Oxford University in 1999 and currently employs 55 professional staff. Oxonica’s mission is to focus on the development of innovative commercial solutions for international markets using its expertise in the design and application of nanomaterials. It owns a diverse portfolio of demand driven products that offer substantial benefits to the target markets of environmental, healthcare and materials.
The company currently has three operating divisions: Oxonica Energy, Oxonica Healthcare and Oxonica Materials. Oxonica has already launched products into international markets. Lead products include:
Oxonica is also active in searching for the next generation of products and is already engaged in developing transformational detection technologies which will enable a new generation of ultrasensitive multiplex diagnostic tools for the clinical diagnostic life science and security markets. In addition, the company is developing other UV absorber technologies into polymer systems and coatings, based on similar technologies to that used in Optisol™.
Oxonica completed a £2.6 million rights issue and employee fundraising (net of expenses) in February 2005. It then completed a £7.1 million placing (net of expenses) and its ordinary shares were admitted to trading on AIM on 20 July 2005. The admission to AIM has raised additional capital for the Group’s development, improved its profile internationally with customers and suppliers and has assisted in the recruitment, retention and incentivisation of employees.
Envirox and Optisol are trademarks of Oxonica. All other trademarks are acknowledged.
For more information, please click here.Internal PR Contact:
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Strength of hair inspires new materials for body armor January 18th, 2017
Self-assembling particles brighten future of LED lighting January 18th, 2017